{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:15:12Z","timestamp":1792602912504,"version":"4.5.0"},"reference-count":18,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2022,4,30]]},"DOI":"10.5582\/bst.2022.01115","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T22:11:17Z","timestamp":1650406277000},"page":"151-157","source":"Crossref","is-referenced-by-count":8,"title":["Time to onset of drug-induced parkinsonism: Analysis using a large Japanese adverse event self-reporting database"],"prefix":"10.5582","volume":"16","author":[{"given":"Kenichiro","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan."},{"name":"Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Niimi","sequence":"additional","affiliation":[{"name":"Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Mano","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Metropolitan Geriatric Center Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Iwatsubo","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan."},{"name":"Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Alvarez MV, Evidente VG. Understanding drug-induced parkinsonism: Separating pearls from oysters. Neurology. 2008; 70:e32-e34.","DOI":"10.1212\/01.wnl.0000302255.49113.51"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. L\u00f3pez-Send\u00f3n J, Mena MA, de Y\u00e9benes JG. Drug-induced parkinsonism. Expert Opin Drug Saf. 2013; 12:487-96.","DOI":"10.1517\/14740338.2013.787065"},{"key":"3","unstructured":"3. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci. 2000; 25:161-166."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France. Mov Disord. 2011; 26:2226-2231.","DOI":"10.1002\/mds.23828"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Brugger F, Bhatia KP, Besag FM. Valproate-Associated parkinsonism: A critical review of the literature. CNS Drugs. 2016; 30:527-40.","DOI":"10.1007\/s40263-016-0341-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sato K, Mano T, Iwata A, Toda T. Safety of memantine in combination with potentially interactive drugs in the real world: A pharmacovigilance study using the Japanese Adverse Drug Event Report (JADER) Database. J Alzheimers Dis. 2021; 82:1333-1344.","DOI":"10.3233\/JAD-210524"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Sato K, Mano T, Iwata A, Toda T. Subtype-dependent reporting of stroke with SGLT2 inhibitors: Implications from a Japanese pharmacovigilance study. J Clin Pharmacol. 2019. doi: 10.1002\/jcph.1561.","DOI":"10.1002\/jcph.1561"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Gedde-Dahl A, Harg P, Stenberg-Nilsen H, Buajordet M, Granas AG, Horn AM. Characteristics and quality of adverse drug reaction reports by pharmacists in Norway. Pharmacoepidemiol Drug Saf. 2007;16:999-1005.","DOI":"10.1002\/pds.1400"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG. Signalling possible drug-drug interactions in a spontaneous reporting system: Delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Br J Clin Pharmacol. 1999; 47:689-693.","DOI":"10.1046\/j.1365-2125.1999.00957.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004; 13:519-523.","DOI":"10.1002\/pds.1001"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Savica R, Grossardt BR, Bower JH, Ahlskog JE, Mielke MM, Rocca WA. Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study. Mov Disord. 2017; 32:227-234.","DOI":"10.1002\/mds.26839"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Han S, Kim S, Kim H, Shin HW, Na KS, Suh HS. Prevalence and incidence of Parkinson's disease and druginduced parkinsonism in Korea. BMC Public Health. 2019; 19:1328.","DOI":"10.1186\/s12889-019-7664-6"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Snyder EM, Murphy MR. Schizophrenia therapy: Beyond atypical antipsychotics. Nat Rev Drug Discov. 2008; 7:471-472.","DOI":"10.1038\/nrd2571"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Shuaib UA, Rajput AH, Robinson CA, Rajput A. Neuroleptic-induced parkinsonism: Clinicopathological study. Mov Disord. 2016; 31:360-365.","DOI":"10.1002\/mds.26467"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chen R. Paradoxical worsening of gait with levodopa in Parkinson disease. Neurology. 2012; 78:446-447.","DOI":"10.1212\/WNL.0b013e318246d6fa"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Wang HM, Liou LM, Hsu CY, Lin HF. Letter to the editor: Donepezil-induced parkinsonism in end-stage renal disease. Neurol Sci. 2021; 42:4809-4812.","DOI":"10.1007\/s10072-021-05522-6"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Armon C, Shin C, Miller P, Carwile S, Brown E, Edinger JD, Paul RG. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology. 1996; 47:626-635.","DOI":"10.1212\/WNL.47.3.626"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Gatto EM, Roca CU, Etcheverry JL, Fadel D. Levetiracetam-induced parkinsonism in a Huntington disease patient. Clin Neuropharmacol. 2006; 29:303-304.","DOI":"10.1097\/01.WNF.0000240946.51994.DF"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/16\/2\/16_2022.01115\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:14:58Z","timestamp":1715231698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/16\/2\/16_2022.01115\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2022.01115","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,30]]},"article-number":"2022.01115"}}